logo-loader
viewVyome Therapeutics Inc.

Vyome Therapeutics expects data from its anti-biotic resistant acne drug end of 2019

Vyome Therapeutics Inc CEO Venkat Nelabhotla sat down with Proactive Investors at the BIO CEO & Investor Conference in New York.

Vyome Therapeutics is a clinical stage speciality pharmaceutical company, with platform technologies and a pipeline of drugs for antibiotic-resistant acne and other skin pathogens.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Buds & Duds: Cannabis stocks struggle as analysts cautious on Canadian sector

The North American Marijuana Index moved 2.3% lower to 128.9 points. The OTCQX Cannabis Index fell 0.4% to 495 points. Buds today were  The Green Organic Dutchman Holdings Ltd (TSE:TGOD) (OTCMKTS:TGODF), CannaRoyaltyCorp (CSE:OH) (OTCMKTS:ORHOF).  Duds were Hexo Corp...

8 hours, 25 minutes ago

2 min read